CDK2 and neoplasm: The buffered cell cycle progression induced by PAX-FOXO1 proteins _a slow cycling state_ could underlie the refractory response of FP-RMS cells to drugs such as CDK2 inhibitors [34] and contribute to the elevated resurgence of tumours post-treatment [92], as shown for other cancers [2].